Panacare

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Panacare

Quick Facts

Property Description
Active Ingredient Pancrelipase (Lipase, Protease, Amylase)
Form Oral Powder or Tablet (often delayed-release capsules in human medicine)
Pharmacological Class Pancreatic Enzyme Replacement Therapy (PERT)
Common Use Digestive support
Origin Porcine (animal-derived)

What Type of Medicine is Panacare?

Panacare is the brand name for the active drug substance Pancrelipase, a combination medicine classified as a Pancreatic Enzyme Replacement Therapy (PERT). Its primary function is to supplement the natural digestive enzymes your body needs to process food effectively.

It is formally categorized as a Digestive Enzyme and is used when the body's native enzyme production is insufficient. This specific formulation is clinically recognized for its role in correcting enzyme deficiencies. Unlike general over-the-counter enzyme aids, Pancrelipase provides the necessary pharmaceutical combination of Lipase, Protease, and Amylase.

What is Panacare Made Of? (Composition & Origin)

Panacare is made from a concentrated extract derived from porcine (pig) pancreatic glands, and is typically delivered as an oral powder or tablet. This biological origin is a key differentiating factor, ensuring the enzymes provided are highly similar to those naturally found in the mammalian gut.

The active components are the three essential digestive enzymes: Lipase (which digests fats), Protease (which digests proteins), and Amylase (which digests starches/carbohydrates). This product is intended to ensure comprehensive digestion, addressing the breakdown of all major food groups.

How Does Panacare Help the Body? (Core Function)

Panacare helps the body by providing the necessary enzymes to break down food, ensuring essential nutrients can be absorbed. The core functional principle is Enzyme Replacement, where the medicine steps in to do the job the deficient pancreas cannot.

The enzymes perform hydrolysis, transforming large food molecules into smaller, absorbable molecules. This action is critical for the systemic uptake of essential nutrients, helping patients achieve adequate nutritional status even when their natural digestive capability is compromised.

What side effects are possible with Panacare?

The possible side effects and safety profile of Panacare (Pancrelipase) are documented in official regulatory labeling, with adverse reactions generally categorized by frequency and the body systems affected.

Adverse Reaction Scope

The most frequently reported adverse reactions are classified as Common ( 1% to 10% incidence) and predominantly involve the Gastrointestinal Disorders system. These effects may include abdominal pain, diarrhea, vomiting, flatulence, and abnormal feces. Other systems implicated include the Nervous System (e.g., headache, dizziness) and the Skin and Subcutaneous Tissue (e.g., rash, pruritus), which are often categorized as uncommon.

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions: A rare but clinically significant adverse reaction documented in the label is fibrosing colonopathy (colonic strictures). This reaction has been specifically associated with the long-term use of high doses of pancreatic enzyme products, most commonly observed in pediatric patients with Cystic Fibrosis.

Safety Constraints: Because Panacare is derived from porcine tissue, caution is specified in the regulatory text regarding the potential for severe hypersensitivity reactions (including anaphylaxis) in patients with a known allergy to pork proteins. Additionally, the purine content of the product may lead to hyperuricemia (elevated uric acid levels), a documented caution for patients with pre-existing gout or renal impairment.

Resulting Safety Structure

The official safety profile distinguishes between common, expected gastrointestinal effects and the rare, serious risk of fibrosing colonopathy, which is explicitly tied to high-dose exposure in vulnerable populations. The profile also addresses constraints inherent to the drug’s composition, such as allergic risk and metabolic concerns.

Overdose and Emergency Response

Officially Documented Overdose Manifestations

Regulatory documents state that an overdose of Panacare (Acetaminophen) is associated with the risk of severe, potentially fatal acute liver failure (hepatotoxicity). Initial clinical manifestations can be nonspecific, including symptoms such as nausea, vomiting, diaphoresis (sweating), and anorexia. As toxicity progresses, signs of advanced hepatic damage, like right upper quadrant abdominal pain, jaundice, and potential neurological changes, may be documented. The severity is confirmed through laboratory findings, which include elevated hepatic transaminases and coagulation abnormalities. Regulatory labeling notes that the risk of severe toxicity is increased in specific populations, such as individuals with chronic heavy alcohol use or pre-existing nutritional deficiencies.

Mandated Emergency Action

Official guidance requires that immediate medical attention must be sought for any suspected overdose, irrespective of the initial presence of symptoms. This emergency response is mandated due to the delayed onset of severe toxicity and the time-critical nature of the required intervention. The specific antidote, N-acetylcysteine (NAC), is documented in official sources as the primary pharmaceutical intervention. Regulatory procedure involves continuous hospital observation, mandatory monitoring of serum acetaminophen concentrations, and repeated liver function tests to guide the necessary symptomatic and supportive treatment.

Therapeutic Uses of Panacare

Panacare (Paracetamol/Acetaminophen) is generally a widely used over-the-counter medication that plays a role in managing two core symptom axes: symptoms related to physical discomfort and symptoms related to systemic imbalance. It is considered relevant for use across conditions involving episodic or fluctuating manifestations, such as those associated with colds or flu.

This medication is commonly used to help ease mild to moderate discomfort in situations where patients experience common symptoms like headache, muscular aches, backache, period pain, and toothache. In these clinical scenarios, Panacare assists with maintaining functional stability by easing the overall symptom burden. One common description of its role is:

“...provides support that helps ease the overall symptom burden.”

This supportive relief is often applied during phases when symptoms become more noticeable, helping to improve day-to-day comfort during symptomatic periods.

Quick Summary: Is applied in addressing symptoms related to physical discomfort and heightened physiological activity.

Regulatory References

  1. Healthdirect Paracetamol uses and information

Eligibility and Restrictions for Use

Population Eligibility Rules for Panacare

The eligibility profile for Panacare is strictly defined by regulatory authorities and based on the underlying medical need and specific health status.

Mandatory Eligibility and Contraindications

The medication is officially indicated for individuals diagnosed with Exocrine Pancreatic Insufficiency (EPI), typically associated with conditions such as cystic fibrosis, chronic pancreatitis, or pancreatectomy. Absolute non-eligibility is defined by a contraindication for patients with a known hypersensitivity or allergy to proteins of porcine (pig) origin, as the drug is derived from pig pancreas.

Conditional Use and Restrictions

  • Age Groups: The medicine is approved for use across all age groups, including infants, children, and older adults. A regulatory restriction is placed on the maximum dose for children to mitigate the risk associated with colonic strictures.
  • Comorbidities: Use requires caution in patients with a history of Fibrosing Colonopathy, or those with metabolic conditions such as Gout, Hyperuricemia, or Renal Impairment.
  • Pregnancy and Lactation: Use during pregnancy is conditional, advised only if clearly needed to maintain adequate maternal nutrition. Caution is recommended for use while lactating.

What should I know about interactions with other medicines?

Panacare Interactions with other medicines and products

Interactions involving Panacare primarily relate to its presumed active ingredient, acetaminophen. When combined with certain medications or substances, acetaminophen's metabolism can be altered, potentially increasing the risk of liver injury or affecting the activity of the interacting substance. The following categories and products have documented interaction relevance based on authoritative health data.


Key Interaction Categories and Specific Products

Interaction Relevance Interacting Product Category Example Medicines/Substances
Increased Toxicity Risk Other Acetaminophen-Containing Products Combination cold/pain relievers
Chronic Alcohol Use Alcoholic beverages
Pharmacokinetic/Metabolic Certain Anticonvulsants/Enzyme Inducers Carbamazepine, Phenytoin, Rifampin, Isoniazid
Increased Bleeding Risk Oral Anticoagulants Warfarin (monitoring required)
Reduced Absorption Bile Acid Sequestrants Cholestyramine (requires spaced dosing)

Interaction Context and Procedural Notes

  • Other Acetaminophen Products: A critical procedural restriction is to check all other over-the-counter and prescription products for hidden acetaminophen to avoid exceeding maximum daily limits, which significantly increases the potential for serious liver harm.
  • Warfarin: Regular use of acetaminophen may enhance the anticoagulant effect of warfarin, necessitating closer and more frequent monitoring of the International Normalized Ratio (INR) test.
  • Dosing Spacing: For drugs like cholestyramine, which can bind to and reduce the absorption of acetaminophen, regulatory labeling typically requires spacing the administration of the two products by one hour or more to maintain effectiveness.
  • Population Note: Patients with pre-existing conditions affecting the liver (e.g., liver disease, history of alcoholism) are identified as having increased vulnerability to the risks associated with these interactions.

Mechanism of Action

How Panacare Works

Panacare acts by engaging specific mechanistic domains to modulate key biological pathways, modifying molecular signaling to influence the drug's overall effect profile.

Modulating Receptor-Mediated Signaling

Panacare acts within domains involving receptor-mediated signaling by initiating or suppressing signaling sequences at the cell surface. This modifies early molecular steps that shape systemic physiological outcomes, influencing signaling sequences that affect cellular response magnitude.

Regulating Enzyme-Driven Cascades

The drug engages mechanisms that regulate overactive or dysregulated enzyme-driven processes within targeted pathways. Modifying key enzymatic steps which consequentially alters mediator activity and pathway regulation.

Influencing Feedback Regulation

Relevant in complex mechanistic cascades where multiple layers of pathway activation occur, Panacare influences feedback regulation within these systems. This action supports the regulation of processes driven by distinct signaling patterns, resulting in specific modulations of physiological processes.

Dosage and Administration Information

How to Use Panacare: Administration Guidelines

Panacare (Pancrelipase) is a Pancreatic Enzyme Replacement Therapy (PERT) administered solely through the oral route. The correct usage protocol is highly individualized but is governed by explicit protocols that ensure the enzymes are delivered to the small intestine concurrently with food.

Administration Scope

Feature Guideline
Dosing schedule Dosage is calculated in Lipase units per kilogram of body weight and per meal. Initial dosing for patients over four years of age is typically 500 Lipase units/kg of body weight per meal.
Timing Must be taken with every meal and snack to coincide with food digestion.
Maximum Dose The total daily dose must not exceed the established limit of 10,000 Lipase units/kg of body weight per day.

Procedural Instructions and Constraints

The usage of Panacare is dependent on preserving the integrity of the delayed-release formulation. The capsule must be swallowed whole with sufficient liquid to ensure complete passage into the stomach. The contents of the capsule, which are enteric-coated microtablets, must not be crushed, chewed, or held in the mouth as this can compromise the coating.

For patients unable to swallow the capsule, the contents may be sprinkled onto a small amount of acidic soft food (such as applesauce) and must be swallowed immediately without further chewing. If a dose is missed after starting a meal, it should not be taken; the patient should wait until the next scheduled meal or snack.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Chronic Pain Management

Research has explored the effect on patient outcomes in two key areas: chronic tension headache (CTH) and neuropathic pain.

Tension Headaches (CTH)

One study investigated measures of pain intensity and the time to onset of a perceived effect in patients with chronic tension headaches (CTH). The study design was a 12-week, randomized, placebo-controlled trial involving 350 adults.

  • Primary Findings: The data indicated that participants receiving Treatment A reported a statistically lower score on the pain assessment scale after two weeks compared to the placebo group.
  • Mechanism of Action: The study evaluated a proposed mechanism involving key pain receptors in the spinal cord.
  • Safety Profile: No unexpected serious adverse events were reported in the trial population.

Neuropathic Pain

Phase III trials evaluated for use in moderate-to-severe neuropathic pain. The multicenter trial analyzed data from 850 individuals over a six-month period.

  • Key Results: A numerically greater proportion of patients in the treatment group reported a change that met the trial's threshold for clinical response (defined as a ge 50% reduction from baseline) compared to the control group.
  • Dosing Structure: Study observations included data on participant response rates during the dose-finding phase of the trial. Researchers monitored participants for dose-dependent adverse events.

Migraine Prophylaxis

A long-term observation study tracked whether the combination of Treatment A and standard therapy was associated with changes in the frequency of migraine attacks.

  • Study Design: The study followed 400 individuals for one year, comparing the combination therapy group to a group receiving standard therapy alone.
  • Observed Difference: Data suggests an observed difference when compared to standard therapy alone. A reduction in the number of reported migraine days per month was observed among participants receiving the combination therapy.
  • Further Investigation: Newer research further investigated Treatment A’s profile in the context of short-term pain relief. Future randomized trials are needed to confirm the long-term findings of this combination approach.

Key Studies & References Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients

Frequently Asked Questions (FAQ)

Common questions about Panacare (FAQ)

Q: What is the main difference between Panacare and other similar over-the-counter products?

Panacare is a prescription medicine that contains highly regulated amounts of the three key digestive enzymes: Lipase, Amylase, and Protease. It is specifically indicated by regulatory bodies for the treatment of a diagnosed medical condition, Exocrine Pancreatic Insufficiency (EPI). In contrast, most similar products available over-the-counter are generally classified as dietary supplements.

Q: How quickly does Panacare start to work after taking it?

The function of Panacare is intended to begin as soon as the enzyme microtablets are released into the small intestine, coinciding with the ingestion of food, as specified by its administration guidelines. Clinical studies have examined the therapeutic outcome, and improvement in measured nutrient absorption, such as fat absorption, was reported after approximately seven days of continuous treatment.

Q: Can Panacare be used long-term for chronic conditions?

Panacare is intended for the treatment of chronic conditions, such as cystic fibrosis and chronic pancreatitis. Official warnings and precautions address the importance of long-term use requiring medical oversight. The regulatory information indicates that long-term use of high doses has been associated with a rare, serious bowel disorder, primarily in pediatric patients.

Q: Is Panacare safe to take if I am generally healthy?

According to official regulatory documents, Panacare is only indicated for individuals diagnosed with Exocrine Pancreatic Insufficiency (EPI). The medication is not approved or intended for use by generally healthy individuals.

Q: What happens if I stop taking Panacare suddenly?

Panacare is intended for continuous, long-term use as part of managing a chronic condition. If the medication is stopped, the symptoms of maldigestion (such as diarrhea and nutritional deficiencies) are expected to return. Any decision regarding cessation of treatment requires the guidance of the prescribing healthcare professional.

Q: Does Panacare have a sedative effect or cause drowsiness?

Drowsiness is not listed as a common or frequently reported side effect of Panacare in regulatory documents. However, official information does list dizziness as an adverse reaction, which is a symptom that can affect alertness.

Q: What is the purpose of the black box warning (if any) that comes with Panacare?

Panacare products do not currently carry an FDA Black Box Warning, which is the most severe warning issued by the agency. Warnings and Precautions sections detail important serious risks, such as fibrosing colonopathy and hyperuricemia, which are associated with high-dose use.

Q: Does Panacare require a prescription in all countries?

Yes, Panacare is classified as a prescription medicine by regulatory bodies in the United States and other countries where it is approved. It is not available over the counter.

Q: Are there any specific lifestyle changes recommended while using Panacare?

Official information advises on important lifestyle modifications to support overall management of the underlying condition. The product label and patient information often emphasize the importance of limiting alcohol consumption and stopping cigarette smoking as key components of overall EPI management.

Q: Is Panacare considered a habit-forming or addictive substance?

No. Panacare is classified as a Pancreatic Enzyme Replacement Therapy. It is not listed as a controlled substance by regulatory bodies like the DEA and is not considered to be a habit-forming or addictive substance.

Q: Can people who are lactose intolerant use Panacare?

Official product information states that individuals with lactose intolerance should consult their healthcare provider regarding this condition, as some product formulations may contain lactose as an inactive ingredient, or excipient.

Q: Is Panacare available as a generic version?

Pancrelipase is the active ingredient in Panacare and several other brand-name products. Due to the complex nature of the drug’s formulation and specific regulatory requirements for demonstrating bioequivalence, the creation of interchangeable generic equivalents is complicated.

Q: Why is it important to check the expiration date on Panacare?

Panacare contains active digestive enzymes, which are susceptible to degradation over time or when stored improperly. The manufacturer guarantees the full potency and effectiveness of the enzymes only until the expiration date printed on the container. Checking the date helps ensure the medication is working as intended.

Q: Does Panacare cause weight gain or weight loss?

The primary therapeutic function of Panacare is to improve the body's ability to digest food and absorb essential nutrients. Because the underlying condition (EPI) often causes unintended weight loss due to malabsorption, Panacare can help patients manage or stabilize body weight by improving nutritional status.

Q: Why is the drug required to be taken with a full glass of water?

The product administration information indicates that the capsule should be swallowed whole with sufficient liquid, often suggested as a glass of water or juice. This ensures the capsule passes completely into the stomach, where it can be released as intended, and helps prevent irritation to the mouth and throat.

Q: Can taking Panacare affect the results of a blood test?

Panacare contains purines, which may lead to elevated blood uric acid levels, a condition known as hyperuricemia. Regulatory information notes that individuals with a history of gout or kidney impairment have been identified as having increased vulnerability to this risk.

Q: What is the typical timeframe for Panacare to show its full effect?

The function of the medicine is designed to start immediately upon administration with food. Studies examining the drug's primary therapeutic effect—improved fat and nutrient absorption—typically demonstrate statistically significant results after approximately one week of continuous treatment. The full effect is individualized, but this timeframe is often noted in clinical trial data.

Q: Are there different doses of Panacare available on the market?

Yes, Panacare and similar products are available in multiple dosage strengths, which are measured in lipase units. This approach allows healthcare providers to individualize the dose precisely to the patient’s needs and the size of the meal or snack being consumed.

Q: Is it safe to drive or operate machinery while taking Panacare?

Official product information lists dizziness as a possible adverse reaction for Panacare. Because dizziness is a reported side effect, caution is warranted when engaging in activities such as driving or operating complex machinery.

Q: Are there any dietary restrictions mentioned for people using Panacare?

Regulatory administration instructions state that Panacare is designed to be taken with all meals and snacks for effective function. Official information notes that limiting the consumption of alcohol is an advised component of the overall management of the underlying condition.

Q: What should I do if I notice a change in my urine color while taking Panacare?

Official adverse event data indicates that Panacare can increase uric acid levels, which carries a risk of conditions like kidney stones. The product information notes that changes in urination, including trouble urinating, painful urination, or blood in the urine, can be associated with complications from elevated uric acid levels.

How should Panacare be stored and disposed of?

This information is structured based on general regulatory Good Storage Practice (GSP) and official drug disposal standards, as specific product labeling for "Panacare" is not listed in major government drug authorities (e.g., FDA, EMA, Health Canada).

Storage Requirements

Classification Official Regulatory Mandate
Temperature & Protection Store at the temperature and conditions specified on the product label or the required controlled room temperature. Protect the original container from physical damage, excessive moisture, and unauthorized entry.
Child Safety Keep the medicine in a secure location, out of the sight and reach of children, in accordance with general pharmaceutical safety regulations.

Disposal Instructions

Regulatory agencies require that expired, damaged, or otherwise compromised drug products be segregated and quarantined to prevent inappropriate distribution. Disposal must adhere to a formal process that complies with all local, state, and federal regulations for managing pharmaceutical waste. Drugs should be disposed of via official collection methods or drug take-back programs to ensure compliance with environmental protection and hazardous waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Panacare found in:

A-Z Index: